BiotechTube
Home/Zevra Therapeutics/Douglas W. Calder
DW

Douglas W. Calder

Nominating and Corporate Governance Committee Chair, Compensation Committee

Zevra Therapeutics

Therapeutic Areas

Rare DiseasesNeurologyMetabolic DisordersGenetic DisordersSleep Disorders

Zevra Therapeutics Pipeline

DrugIndicationPhase
MIPLYFFA® (arimoclomol)Niemann-Pick disease type C (NPC)Filed (EU)
OLPRUVA®Urea Cycle Disorders (UCDs)Approved
CeliprololVascular Ehlers-Danlos Syndrome (VEDS) - COL3A1 positivePhase 3
KP1077Idiopathic Hypersomnia / Sleep DisordersPhase 2

Leadership Team at Zevra Therapeutics

NF
Neil F. McFarlane
President & Chief Executive Officer
JR
Justin Renz
Chief Financial Officer
JS
Joshua Schafer
Chief Commercial Officer
AQ
Adrian Quartel, M.D., FFPM
Chief Medical Officer
RW
Rahsaan W. Thompson
Chief Legal Officer, Secretary and Compliance Officer
AP
Alison Peters
Chief People Officer
TH
Tanya Hayden
Senior Vice President, Chief of Staff
GO
Gerald Orehostky
Senior Vice President, Regulatory Affairs and Quality
CM
Christopher M. Lauderback, PhD
Senior Vice President, Manufacturing
TS
Timothy Sangiovanni, CPA
Senior Vice President, Finance and Corporate Controller
View full Zevra Therapeutics profile